Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Vaccine Therapy in Treating Patients With Kidney Cancer

Phase 1

Completed

Conditions: Kidney Cancer

Interventions: Biological: human prostate-specific membrane antigen plasmid DNA vaccine
Biological: mouse prostate-specific membrane antigen plasmid DNA vaccine

First Posted Date: 2004-11-15

Last Posted Date: 2018-04-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 15

Registration Number: NCT00096629

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

First Posted Date: 2004-11-10

Last Posted Date: 2013-01-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00096525

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: everolimus
Drug: gefitinib

First Posted Date: 2004-11-10

Last Posted Date: 2016-01-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 74

Registration Number: NCT00096486

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma

Not Applicable

Completed

Conditions: Sarcoma

Interventions: Drug: valganciclovir

First Posted Date: 2004-11-10

Last Posted Date: 2015-11-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 6

Registration Number: NCT00096538

Locations: 🇺🇸
Memorial Sloan - Kettering Cancer Center, New York, New York, United States
🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

First Posted Date: 2004-10-08

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00093405

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-09-14

Last Posted Date: 2013-04-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 25

Registration Number: NCT00003956

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors

Phase 1

Completed

Conditions: Head and Neck Cancer
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-09-13

Last Posted Date: 2013-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 40

Registration Number: NCT00003430

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Hormone Therapy in Treating Women With Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-09-13

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 114

Registration Number: NCT00003428

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas

Phase 1

Completed

Conditions: Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-09-13

Last Posted Date: 2013-06-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 40

Registration Number: NCT00004057

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors

Phase 2

Completed

Conditions: Extragonadal Germ Cell Tumor
Ovarian Cancer

First Posted Date: 2004-08-30

Last Posted Date: 2013-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002489

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy